But again, just because an investment is short-term in nature and generally considered to be safe, it doesn’t mean there’s no chance of losses. There are some short-term investing strategies ...
Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as ...